AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19
Shots:
- The collaboration will bring Oxford’s recombinant adenovirus vaccine- ChAdOx1 nCoV-19 to the patients and will enable AstraZeneca to be responsible for the development and WW manufacturing and distribution of the vaccine
- The alliance will combine Oxford’s expertise in vaccinology and AstraZeneca’s global development- manufacturing and distribution capabilities to combat the pandemic
- ChAdOx1 is based on adenoviral vector technology and has entered P-I clinical study last week to evaluate its safety and efficacy in healthy volunteers aged 18-55yrs.- across five centers in Southern England with its anticipated results in next month and the expected advancement to late-stage studies by the middle of the year
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com